Efficacy and prognostic factors of anrotinib hydrochloride in the treatment of advanced hepatocellular carcinoma
Objective To observe the effect of treating advanced hepatocellular carcinoma(HCC)patients with anrotinib hydrochloride,and analyze the influencing factors of patients'prognosis.Methods The clinical data of 80 pa-tients with advanced HCC who were treated in Nanyang Second People's Hospital from January 2021 to January 2023 were retrospectively analyzed,and the curative effect and adverse reactions of patients treated with anrotinib hydrochlo-ride for one cycle were evaluated.Patients who died within one year were included in the poor prognosis group(n=30),and those who survived were included in the good prognosis group(n=50).Multivariate COX regression was used to an-alyze the factors affecting the prognosis of patients with advanced HCC.Results After one cycle of treatment,among the 80 patients with advanced HCC,0 had complete remission,24 had partial remission,41 had stable disease,and 15 had progressive disease,with the disease control rate of 81.25%.The adverse reactions of anotinib hydrochloride in the treatment of advanced HCC included hypertension(30.00%),fatigue(36.25%),diarrhea(16.25%),and nausea(10.00%).Thirty of the 80 patients with advanced HCC died within one year of follow-up,and the overall survival(OS)was 9.8 months(95%CI:7.5 to 10.8).Univariate COX regression analysis showed that there was no significant difference in age,gender,body mass index,prothrombin time,Child-Pugh score,alpha-fetoprotein,alanine amino-transferase,aspartate aminotransferase,hepatitis B virus positive,cirrhosis rate,portal hypertension rate,portal vein tu-mor thrombus rate,extrahepatic metastasis rate,ascites rate,and splenomegaly rate between the patients with good prognosis and those with poor prognosis(P>0.05).However,the proportions of patients with Eastern Cooperative On-cology Group(ECOG)score of 2 and those with the rate of albumin<35 g/L in patients with poor prognosis were 76.67%and 86.67%,which were significantly higher than 30.00%and 34.00%in patients with good prognosis(P<0.05).Multivariate COX regression analysis showed that ECOG score of 2 and albumin<35 g/L were risk factors for the prognosis of patients with advanced HCC(P<0.05).Conclusion Anlotinib hydrochloride is safe and effective in the treatment of advanced HCC.High ECOG score and decreased albumin are risk factors affecting the prognosis of patients with advanced HCC.
万方数据
维普
